19 January 2023 - Since its launch in December 2017, ixazomib has been funded through the Cancer Drugs Fund and has become a preferred treatment option in this setting having been used to treat over 4,000 patients in England alone.

Takeda UK is pleased to announce that NICE has recommended Ninlaro (ixazomib) with lenalidomide and dexamethasone as an option for treating relapsed or refractory multiple myeloma in adult patients who have received two or three lines of therapy, within a final appraisal document published today.

Read Takeda press release